REYKJAVIK, Iceland, March 28, 2023 (GLOBE NEWSWIRE) -- Alvotech (Nasdaq: ALVO) (the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced an update to the …
Alvotech to present two posters related to pharmacokinetics and confirmatory clinical studies for AVT04 (ustekinumab), a proposed biosimilar to Stelara® Marketing applications for AVT04 have been submitted in major markets including U.S. and Europe …
News tech company Newsmatics recently launched a news propaganda identification service that can help readers avoid falling into the trap of fake news. WASHINGTON , D.C., USA, March 1, 2023 /EINPresswire.com/ -- At a recent congressional hearing, …
Full year 2022 total revenue, including other income, increased by 114% to $85.0 million, compared to $39.7 million in 2021, driven by both milestone revenue and product revenue from commercialization of AVT02, a biosimilar to Humira®, in 17 countries …
4IR Tokens can be used as a means of payment to acquire goods for products and services that will be offered on the E-commerce Platform, and incentive rewards PARIS, FRANCE, February 28, 2023 /EINPresswire.com/ -- Blockchain Valley SAS (“ …
REYKJAVIK, Iceland, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that it will release financial results …
REYKJAVÍK, Iceland, Feb. 23, 2023 (GLOBE NEWSWIRE) -- Icewear, the leading manufacturer and retailer of Icelandic wool products, has been operating in a changing market environment. One could say that responding to the travel restrictions and influxes in …
REYKJAVIK, Iceland, Feb. 10, 2023 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today the completion of the equity transaction …
Partners Alvotech and STADA have marketing authorization application (MAA) for ustekinumab accepted for filing by the European Medicines Agency (EMA) BAD VILBEL, HESSEN, GERMANY, February 9, 2023 /EINPresswire.com/ -- EMA Confirms Acceptance of …
Partners Alvotech and STADA have marketing authorization application (MAA) for ustekinumab accepted for filing by the European Medicines Agency (EMA) EMA opinion on AVT04 could come as soon as the second half of 2023 Reference product Stelara® (ustekinumab …
Advanz Pharma will commercialize AVT23, a proposed biosimilar to Xolair® (omalizumab) in the European Economic Area, UK, Switzerland, Canada, Australia, and New Zealand REYKJAVIK, Iceland, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global …
AVT02 as Simlandi™ is the first biosimilar approved under the strategic partnership between Alvotech and Bioventure REYKJAVIK, Iceland and DUBAI, United Arab Emirates, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO) and Bioventure, a wholly …
REYKJAVIK, Iceland, Jan. 23, 2023 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the completion of a private placement of …
Proceeds of global competition's new category to benefit The Michael James Jackson Foundation to fund scholarships for people of color entering brewing industry MELVILLE, NEW YORK, USA, January 16, 2023 /EINPresswire.com/ -- In the spirit of giving, …
REYKJAVIK, Iceland and TOKYO, Jan. 13, 2023 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Japanese pharmaceutical company Fuji …
REYKJAVIK, Iceland, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today the initiation of a pharmacokinetic …
Results show Automated Pupillometer and NPi® can be used for patient evaluation and triage without risk of confounding by key intoxicants of abuse IRVINE, CALIF., USA, January 10, 2023 /EINPresswire.com/ -- A newly published clinical study shows that …
The U.S. Food and Drug Administration’s (FDA) regulatory review is anticipated to be completed in the second half of 2023 Stelara® (ustekinumab) is prescribed to treat a variety of inflammatory conditions REYKJAVIK, Iceland and PARSIPPANY, N.J., Jan. 06, …
U.S. Food and Drug Administration (FDA) has confirmed that the goal date for an approval decision on Alvotech’s license application for AVT02 is April 13, 2023 FDA has completed review of Alvotech’s application of AVT02 as an interchangeable to high- …
Reference is made to the announcement issued earlier today about the completion of a private placement of subordinated convertible bonds. The aggregate principal amount is approximately US$70 million, instead of US$59.7 million. Please see correction below …
02 days 02:51:36
